News and Press Releases

Contact Veristat Now


Request A Proposal

Contact Us

Veristat congratulates Awakn - UK State Funding to Identify Optimal Pathway to Market In UK & US

Veristat congratulates Awakn for being awarded UK State Funding to Identify Optimal Pathway to Market In UK & US For Its Lead Clinical Development Program – Ketamine-Assisted Therapy For Alcohol Use Disorder

Read More

Veristat Congratulates Origin Biosciences for FDA Approval

Veristat Congratulates Origin Biosciences for FDA Approval of Nulibry during the Week of Rare Disease Day 2021

Read More

Veristat Supported Marketing Applications for 10% of all FDA Novel Drug Approvals in 2020

Strengthening its Track Record of Successful Client Regulatory Approval Outcomes

SOUTHBOROUGH, MA – January 14, 2021 – Veristat, a scientific-minded global clinical research organization (CRO), announced today that they supported the marketing applications for 10% of the 2020 US Food and Drug Administration (FDA) novel drug approvals. The FDA approved 53 novel drugs, defined by the FDA as New Molecular Entities (NMEs)[i], and Veristat regulatory, statistical, and medical writing experts were integral in preparing five of these NME New Drug Applications. Veristat also prepared NDA/BLAs for three non-NME FDA approvals and one Marketing Authorization Application (MAA) that received approval in Europe.

Read More

Veristat Announces Global Cell and Gene Therapy Center of Excellence

Accelerating cell and gene therapy opportunities for patients by advancing access to knowledge and leveraging experience for sponsors to increase program success

SOUTHBOROUGH, MA – October 22, 2020 – Cell and gene therapies represent the next great wave of therapeutic innovation and have led to the development of promising therapies worldwide.

Read More

Veristat Strengthens Its European Presence with the Acquisition of TCTC

Increasing Its Footprint and Expanding Therapeutic Expertise to Guide Sponsors Throughout the Clinical Development Lifecycle

Read More

Veristat Strengthens Its Regulatory Expertise with the Acquisition of Catalyst Regulatory Services

Expanding Its Team of Regulatory Experts to Guide Biopharmaceutical Sponsors Along the Pathway to Market Approval

 

Read More

Veristat Supports 12% of all FDA NME Approvals in 2018, a Record-Setting Year for FDA Approvals

Veristat Celebrates Its Support of over 75 Global Regulatory Submissions Since Its Founding

 

Read More

Veristat Strengthens Clinical Operations Capabilities - Acquires Topstone Research

Expanding Its Clinical Operations and Biometrics Teams Dedicated to Emerging, Small and Mid-Sized Biopharma

Read More

Veristat Congratulates Alnylam on the FDA Approval of ONPATTRO™

Continues Collaboration to Provide Regulatory Submission Support for
Additional Patisiran Submissions

 

SOUTHBOROUGH, MA –  August 20, 2018 –   Veristat, a full service Clinical Research Organization (CRO), congratulates Alnylam on the recent FDA approval of ONPATTRO™ (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. 

Read More